SCHEMBL6581783

SCHEMBL6581783

[c]1c(-c2occ3ccccc23)sc2ccccc12

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
GPR3 P46089 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL467485 0.69 ALDH1A1 (0.32)
SCHEMBL5069072 0.68
SCHEMBL547394 0.67 APP (0.46)
SCHEMBL2965431 0.66 ALDH1A1 (0.33) GPR3
SCHEMBL6992749 0.66 CYP2A6 (0.38) GPR3
SCHEMBL14797024 0.65
SCHEMBL4585151 0.64 ALOX5 (0.39)
SCHEMBL7231262 0.64
SCHEMBL712886 0.62 ENPP3 (0.32)
SCHEMBL5917524 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0891340-B1 OXAZOLE DERIVATIVES, THEIR PRODUCTION AND USE TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2002-11-13 EP claimed
EP-3676263-B1 3-HYDROXY-IMIDAZOLIDIN-4-ONE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE NETHERLANDS TRANSLATIONAL RES CENTER B V (NL) 2021-10-06 EP disclosed
EP-3484867-B1 INHIBITORS OF TRYPTOPHAN 2,3-DIOXYGENASE NETHERLANDS TRANSLATIONAL RES CENTER B V (NL) 2021-04-28 EP disclosed
EP-3676263-A1 3-HYDROXY-IMIDAZOLIDIN-4-ONE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE Netherlands Translational Research Center B.V. (NL) 2020-07-08 EP disclosed
EP-3426638-B1 INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE NETHERLANDS TRANSLATIONAL RES CENTER B V (NL) 2020-05-06 EP disclosed
EP-3484867-A1 INHIBITORS OF TRYPTOPHAN 2,3-DIOXYGENASE Netherlands Translational Research Center B.V. (NL) 2019-05-22 EP disclosed
WO-2019043103-A1 3-HYDROXY-IMIDAZOLIDIN-4-ONE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) 2019-03-07 WO disclosed
EP-3426638-A1 INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE Netherlands Translational Research Center B.V. (NL) 2019-01-16 EP disclosed
WO-2018011227-A1 INHIBITORS OF TRYPTOPHAN 2,3-DIOXYGENASE NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) 2018-01-18 WO disclosed
EP-3269714-A1 INHIBITORS OF TRYPTOPHAN 2,3-DIOXYGENASE Netherlands Translational Research Center B.V. (NL) 2018-01-17 EP disclosed
WO-2017153459-A1 INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) 2017-09-14 WO disclosed
US-20040058965-A1 Alkanoic acid derivatives process for their production and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058965-A1 Alkanoic acid derivatives process for their production and use thereof GPR119, ACOX1, ALK GPR3 710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.